Lastly, Sacituzumab govitecan is an ADC targeting trophoblast cell-surface antigen 2 (Trop-2) that was investigated in the phase 2 TROPiCS-03 basket trial in patients with treatment-refractory HNSCC (88). This evidence concerns the gene TACSTD2 and head and neck squamous cell carcinoma.